Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
作者信息
Coyle J, Hobson P, Meara J
出版信息
J Neurol Neurosurg Psychiatry. 1998 Aug;65(2):280; author reply 281-2.
Abstract
摘要
相似文献
1
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1998 Aug;65(2):280; author reply 281-2.
2
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1998 Aug;65(2):280-2.
3
[Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Rev Neurol (Paris). 1996 Feb;152(2):103-5.
4
Deprenyl in Parkinson's disease.
Ann Neurol. 1996 Aug;40(2):268-9. doi: 10.1002/ana.410400229.
5
Selegiline in Parkinson's disease.
BMJ. 1995 Dec 16;311(7020):1583-4. doi: 10.1136/bmj.311.7020.1583.
6
Deprenyl and levodopa and Parkinson's disease progression.
Ann Neurol. 1996 Aug;40(2):267-8. doi: 10.1002/ana.410400228.
7
Selegiline and excess mortality.
Clin Neuropharmacol. 1997 Dec;20(6):542. doi: 10.1097/00002826-199712000-00006.
8
Treatment of Parkinson's disease.
Curr Opin Neurol Neurosurg. 1993 Jun;6(3):339-43.
9
Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.
Parkinsonism Relat Disord. 2003 Mar;9(4):221-4. doi: 10.1016/s1353-8020(02)00053-6.
10
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
BMJ. 1998 Apr 18;316(7139):1191-6. doi: 10.1136/bmj.316.7139.1191.
Zotero 插件